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1Background—The safety and efficacy of new-generation drug-eluting stents (DES) in women with multiple atherothrombotic 
risk (ATR) factors is unclear.
Methods and Results—We pooled patient-level data for women enrolled in 26 randomized trials. Study population was categorized 
based on the presence or absence of high ATR, which was defined as having history of diabetes mellitus, prior percutaneous or 
surgical coronary revascularization, or prior myocardial infarction. The primary end point was major adverse cardiovascular 
events defined as a composite of all-cause mortality, myocardial infarction, or target lesion revascularization at 3 years of follow-
up. Out of 10 449 women included in the pooled database, 5333 (51%) were at high ATR. Compared with women not at high 
ATR, those at high ATR had significantly higher risk of major adverse cardiovascular events (15.8% versus 10.6%; adjusted 
hazard ratio: 1.53; 95% confidence interval: 1.34–1.75; P=0.006) and all-cause mortality. In high-ATR risk women, the use 
of new-generation DES was associated with significantly lower risk of 3-year major adverse cardiovascular events (adjusted 
hazard ratio: 0.69; 95% confidence interval: 0.52–0.92) compared with early-generation DES. The benefit of new-generation 
DES on major adverse cardiovascular events was uniform between high-ATR and non–high-ATR women, without evidence 
of interaction (Pinteraction=0.14). At landmark analysis, in high-ATR women, stent thrombosis rates were comparable between 
DES generations in the first year, whereas between 1 and 3 years, stent thrombosis risk was lower with new-generation devices.
Conclusions—Use of new-generation DES even in women at high ATR is associated with a benefit consistent over 3 years 
of follow-up and a substantial improvement in very-late thrombotic safety.  (Circ Cardiovasc Interv. 2016;9:e002995. 
DOI: 10.1161/CIRCINTERVENTIONS.115.002995.)
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Atherothrombosis is a life-threatening condition in which rupture of a high-risk plaque can lead to thrombosis and 
occlusion of an artery, in turn causing symptoms of periph-
eral ischemia, stroke, or acute coronary syndrome.1 Currently, 
atherothrombotic disorders of the coronary, cerebrovascu-
lar, and peripheral arterial vasculature are the leading cause 
of mortality worldwide. In fact, according to the American 
Heart Association, over 1.1 million Americans in 2010 were 
hospitalized with acute coronary syndrome.1,2 Importantly, 
about 488 000 of these patients were women.2 Women also 
constitute about one third of all patients treated with percu-
taneous coronary intervention (PCI) with drug-eluting stent 
(DES) implantation.2 However, women have been underrep-
resented in randomized controlled trials (RCTs) that inves-
tigated the safety and efficacy of DES. In the 2011 Food 
and Drug Administration’s guidance document, gender dis-
parities in RCTs investigating medical devices were identi-
fied and addressed. In response to the recommendations 
expressed by the Food and Drug Administration, the Society 
for Cardiovascular Angiography and Interventions’ Women in 
Innovation Initiative organized a Gender Data Forum in which 
the outcomes of DES in women were addressed. This led to 
the creation and analysis of the present large individual female 
patient–level pooled data set from existing randomized trials 
of DES.
Although trials investigating pharmacotherapies targeting 
key molecular and cellular players in the pathogenesis of arte-
rial thrombosis have been conducted in patients with multiple 
atherothrombotic risk (ATR) factors,3–5 to date, few data are 
available regarding the relative safety and efficacy of new-
generation DES in such a high-risk population, especially 
of female sex. With the hypothesis that presence of durable 
multiple ATR factors might attenuate the benefits associated 
with new-generation DES, in the present patient-level pooled 
analysis of RCTs, we sought to evaluate the prognostic impact 
of a study-defined high-ATR in women undergoing PCI and 
the safety and efficacy of new-generation DES, compared 
with early-generation, in women with or without high ATR.
Methods
Study Design and Population
The rationale of the present patient-level pooled database, list of tri-
als, analytic strategies, and prespecified end points has been previous-
ly reported.6 Briefly, female participants from 26 RCTs were pooled: 
RAVEL (The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal 
Stent Study), SIRIUS (Study of Sirolimus-Coated BX VELOCITY 
Balloon-Expandable Stent in Treatment of de Novo Native Coronary 
Artery Lesions), E-SIRIUS (The Study of the BX VELOCITY Stent 
in Patients With De Novo Coronary Artery Lesions), C-SIRIUS (The 
Study of the BX Velocity Stent in the Treatment of De Novo Artery 
Lesions), TAXUS-I (Randomized, Double-Blind Trial on a Slow-
Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions), 
TAXUS-II SR (A Randomized Study to Assess the Effectiveness 
of Slow- and Moderate- Release Polymer-Based Paclitaxel-
Eluting Stents for De Novo Coronary Artery Lesions), TAXUS-IV 
(Treatment of De Novo Coronary Disease Using a Single Paclitaxel-
Eluting Stent), TAXUS-V (A Randomized, Double-Blind Trial to 
Assess TAXUS Paclitaxel-Eluting Coronary Stents, SR Formulation, 
in the Treatment of De Novo Coronary Lesions), SIRTAX 
(Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary 
Revascularization), ENDEAVOR II (Randomized Controlled Trial 
to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-
578 Eluting Driver Coronary Stent in De Novo Native Coronary 
Artery Lesions), ENDEAVOR III (A Randomized Controlled Trial 
of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent 
System Versus the Cypher Sirolimus-Eluting Coronary Stent System 
in De Novo Native Coronary Artery Lesions), ENDEAVOR-IV 
(Randomized Comparison of Zotarolimus-Eluting and Paclitaxel-
Eluting Stents in Patients With Coronary Artery Disease), SPIRIT 
II (A Clinical Evaluation of the XIENCE V Everolimus Eluting 
Coronary Stent System in the Treatment of Patients With de Novo 
Native Coronary Artery Lesions), SPIRIT III (A Clinical Evaluation 
of the Investigational Device XIENCE V Everolimus Eluting 
Coronary Stent System in the Treatment of Subjects With de Novo 
Native Coronary Artery Lesions), SPIRIT IV (Clinical Evaluation 
of the XIENCE V Everolimus Eluting Coronary Stent System in 
the Treatment of Subjects With de Novo Native Coronary Artery 
Lesions), BASKET-PROVE (Evaluation of Late Clinical Events 
After Drug-Eluting Versus Bare-Metal Stents in Patients at Risk: 
Basel Stent Kosten Effektivitäts Trial - Prospective Validation 
Examination Part II), COMPARE I (A Randomized Controlled 
Trial of Everolimus Eluting Stents and Paclitaxel-Eluting Stents 
for Coronary Revascularization in Daily Practice), COMPARE 
II (Comparison of the Everolimus Eluting With the Biolimus A9 
Eluting Stent), EXCELLENT (The Efficacy of Xience/Promus 
Versus Cypher to Reduce Late Loss After Stenting), RESET 
(Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy 
Following Endeavor Zotarolimus-Eluting Stent Implantation), 
RESOLUTE AC (Randomized, Two-Arm, Non-Inferiority Study 
Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent), 
TWENTE (The Real-World Endeavor Resolute Versus XIENCE V 
Drug-Eluting Stent Study in Twente), LEADERS (A Randomized 
Comparison of a Biolimus-Eluting Stent With a Sirolimus-Eluting 
Stent for Percutaneous Coronary Intervention), ISAR TEST 4 
(Prospective, Randomized Trial of 3-Limus Agent-Eluting Stents 
With Different Polymer Coatings), PRODIGY (Prolonging Dual 
Antiplatelet Treatment in Patients With Coronary Artery Disease 
After Graded Stent-Induced Intimal Hyperplasia Study), and 
PROTECT (Patient Related Outcomes With Endeavor Versus 
Cypher Stenting Trial) (full reference list included in the Appendix 
WHAT IS KNOWN
•	Concomitance of multiple atherothrombotic risk 
factors enhance propensity for coronary ischemic 
events and mortality.
•	 Increased platelet inhibition is beneficial in patients 
at high risk for atherothrombotic events. However, 
whether the improved biocompatibility and anti-
thrombotic properties of new-generation drug-elut-
ing stent are preserved in women at high athero-
thrombotic risk is unknown.
WHAT THE STUDY ADDS
•	 In women at high atherothrombotic risk, compared 
with early-generation drug-eluting stent, new-gen-
eration devices are associated with preserved safety 
and efficacy over 3 years of follow-up and with a 
substantial benefit in very-late (>1 year) stent-related 
thrombotic safety.
•	 In women not at high atherothrombotic risk, new-
generation drug-eluting stents were associated with 
an exceedingly low risk of very-late (>1 year) stent 
thrombosis at 3 years of follow-up.
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in the Data Supplement). Characteristics of the RCTs included in the 
present study are summarized in the Table I in the Data Supplement. 
All the included RCTs were performed between 2000 and 2013. 
The study population was stratified into 2 categories based on the 
presence or absence of high ATR (Table 1). Women who received 
a bare-metal stent were excluded from this analysis. ATR was de-
fined as the composite of history of diabetes mellitus (DM), pre-
vious revascularization (PR; defined as previous PCI or previous 
coronary artery bypass graft), or previous myocardial infarction 
(PMI). The rationale of such definition is based on the criteria used 
in the Clopidogrel for High Atherothrombotic Risk and Ischemic 
Stabilization, Management and Avoidance (CHARISMA)3 accord-
ing to the available clinical variables included in the pooled data set. 
Moreover, each one of these risk factors previously demonstrated to 
be associated with substantial increased risk for adverse events in 
patients undergoing PCI.7–9
All trials included in our analysis complied with the provisions 
of the Declaration of Helsinki, and the institutional review board at 
each study center approved the study protocols. All patients provided 
written informed consent for participation in each study.
Drug-Eluting Stents
The following DES have been included in the present analysis: siro-
limus-eluting stents (Cypherand Cordis, Johnson & Johnson, Miami 
Lakes, FL), paclitaxel-eluting stents (Taxus, Boston Scientific, Natick, 
MA), everolimus-eluting stents (Xience, AbbottVascular, Santa 
Clara, CA; Promus, Boston Scientific), zotarolimus-eluting stents 
(Endeavor, Medtronic, Santa Rosa, CA; Resolute, Medtronic), bio-
limus-eluting stents with biodegradable polymer coating (Biomatrix, 
Biosensors, Newport Beach, CA; Nobori, Terumo, Tokyo, Japan), 
and sirolimus-eluting stents with biodegradable polymer coating 
(Yukon, Translumina, Hechingen, Germany).
Coronary stents used among trials were classified as early-gen-
eration DES (including sirolimus- and paclitaxel-eluting stents) and 
new-generation DES (including everolimus and zotarolimus stents 
Table 1. Baseline Clinical and Angiographic Characteristics According to High-
Atherothrombotic Risk Status
High-ATR  
(N=5333; 51.0%)
No High-ATR  
(N=5116; 49.0%) P Value
Age 67.9±10.3 66.5±10.9 <0.0001
BMI 29.2±6.3 27.2±5.3 <0.0001
Cardiac risk factors
  Diabetes mellitus 3294 (61.8%) 0 (0.0%) <0.0001
  IDDM 1053 (32.0%) … …
  Arterial hypertension 4403 (82.6%) 3478 (68.0%) <0.0001
  Hypercholesterolemia 3982 (74.8%) 3060 (60.0%) <0.0001
  Current or former smoking 1225 (23.1%) 1587 (31.1%) <0.0001
  Family history of CAD 1918 (39.0%) 1885 (39.1%) 0.91
  Previous MI 1915 (36.1%) 0 (0.0%) <0.0001
  Previous PCI 2136 (41.0%) 0 (0.0%) <0.0001
  Previous CABG 522 (9.8%) 0 (0.0%) <0.0001
Clinical presentation <0.0001
  Stable angina 3147 (60.9%) 2613 (52.6%)
  Unstable angina 1204 (23.3%) 993 (20.0%)
  NSTEMI 618 (12.0%) 779 (15.7%)
  STEMI 196 (3.8%) 583 (11.7%)
  LVEF, % 54.4±17.2 56.8±17.5 <0.0001
Angiographic characteristics
  Number of lesions treated 1.30±0.62 1.27±0.59 0.04
  Number of stents implanted 1.55±0.94 1.52±0.90 0.04
  Mean stent diameter, mm 3.0±0.4 3.0±0.4 <0.0001
  Total stent length, mm 30.1±19. 6 29.0±18.4 0.004
  Type B2/C lesion 2804 (64.6%) 2447 (61.5%) 0.003
  Moderate/severe calcifications 900 (26.9%) 722 (23.8%) 0.005
  Bifurcation lesion 498 (19.9%) 456 (19.4%) 0.69
Type of stent implanted <0.0001
  Early-generation stent 2146 (40.2%) 2025 (39.6%)
  New-generation stent 3187 (59.8%) 3091 (60.4%)
Results reported as n (%) or mean±standard deviation as appropriate. ATR indicates atherothrombotic risk; BMI, body 
mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; DES, drug-eluting stent; IDDM, insulin-
dependent diabetes mellitus; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSTEMI, non–ST-segment–
elevation myocardial infarction; PCI, percutaneous coronary intervention; SA, stable angina; STEMI, ST-segment–elevation 
myocardial infarction; and UA, unstable angina.
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with durable polymer and biolimus- and sirolimus-eluting stents with 
biodegradable polymer).
Study Objectives and End Points Definitions
The objectives of the present study were (1) to characterize the impact 
of multiple ATR factors on outcomes in women undergoing PCI with 
DES and (2) to evaluate the safety and efficacy of new-generation 
DES, compared with earlier generation, in women at high ATR. The 
primary end point of the current study was the risk of major adverse 
cardiac events (MACE). MACE was defined as the composite of all-
cause mortality, myocardial infarction (MI), or target-lesion revascu-
larization. Additional end points were the individual components of 
MACE, cardiac mortality, definite or probable stent thrombosis (ST), 
and the composite of all-cause mortality, MI, or definite or probable 
ST. The clinical end point definitions used across trials are detailed in 
Table II in the Data Supplement.
Statistical Analysis
All patient-level data were aggregated and combined as one data set 
on a prespecified extraction sheet. Baseline clinical, demographic, 
and procedural characteristics of the study groups were reported as 
mean±standard deviation for continuous variables and as propor-
tions for categorical variables. Continuous variables were compared 
with student t test. Categorical variables were compared with χ2 test. 
Cumulative event rates in the study groups were calculated with the 
Kaplan–Meier method and compared with the log-rank test. For 
these analyses, the total follow-up was defined as the time from in-
dex procedure until death, last follow-up date, or 3 years, whichever 
came first. Additionally, we performed Kaplan–Meier analyses in the 
landmark periods of zero to 1 year and of 1 to 3 years to evaluate 
the impact of DES generation on thrombotic end points at different 
time periods. The independent associations between high ATR, stent 
generation, and outcomes were assessed with the Cox proportional 
hazards models that included a frailty term (γ) to assess random ef-
fects in the trials. Frailties are the unmeasured factors that affect trial-
specific baseline risk and are distributed as γ random variables with 
a mean of 1 and variance θ. The variance parameter was interpreted 
as a metric of heterogeneity in baseline risk between trials. In the 
adjusted analysis evaluating the impact of high ATR on outcomes, no 
high ATR was the reference category. For the DES-level analysis, ear-
ly-generation DES was the reference category. Multivariable models 
included covariates that significantly differed at univariate analysis 
and those deemed clinically relevant from previous studies (without 
including variables that are intrinsically part of the composite ATR 
definition). The full list of covariates included in the multivariable 
models is listed in the footnotes of the tables. The proportionality 
assumption was verified by means of scaled Schoenfeld residual. 
Multicollinearity was evaluated by means of visual inspection of cor-
relation matrix and estimation of the variance inflation factor, with 
>10 used as a threshold to define significant multicollinearity. For the 
DES-level analysis, the consistency of the effect of new-generation 
DES in women with or without high ATR was evaluated with formal 
interaction test. We judged P values of <0.05 to be significant, and all 
analyses were done with SAS software.
Results
Baseline Characteristics
Out of 10 449 women included in the pooled database, 5333 
(51%) were at high ATR (Figure 1). Clinical characteristics 
according to high ATR are reported in Table 1. Women with 
high ATR were older, had higher body mass index, and had 
greater prevalence of arterial hypertension and hypercholes-
terolemia. Patterns of clinical presentation significantly dif-
fered between groups: women at high ATR had more stable 
phenotypes and women without high ATR had higher preva-
lence of MI presentation. Angiographic and procedural data 
are reported in Table 1. Women with high ATR had a higher 
number of lesions treated, stents implanted, American Col-
lege of Cardiology/American Heart Association type B2/C 
lesions, moderate or severe calcifications, and greater total 
stent length.
Impact of High ATR Status on 3-Year Clinical 
Outcomes
Unadjusted and adjusted clinical outcomes according to high-
ATR status are reported in Table 2. A significantly higher 
crude rate of MACE was observed in women with versus with-
out high ATR (Figure 2A; 15.8 % versus 10.6%; P<0.0001). 
Women with high ATR also had higher rates of all-cause mor-
tality (Figure 2B), cardiac mortality, MI, target-lesion revas-
cularization, definite or probable ST, and the composite of 
all-cause mortality, ST, or MI.
Following multivariable adjustment, high ATR status was 
independently associated with higher risk of MACE (adjusted 
hazard ratio [HR]: 1.53; 95% confidence interval [CI]: 1.34–
1.75; P<0.0001), all-cause mortality (adjusted HR: 2.10; 
95% CI: 1.66–2.66; P<0.0001), cardiac mortality (adjusted 
HR: 2.35; 95% CI: 1.71–2.23; P<0.0001), MI (adjusted HR: 
1.32; 95% CI: 1.06–1.64; P=0.01), target-lesion revascular-
ization (adjusted HR: 1.49; 95% CI: 1.22–1.81; P<0.0001), 
ST (adjusted HR: 2.23; 95% CI: 1.42–3.49; P<0.0001), and 
the composite of all-cause mortality, MI, or ST (adjusted HR: 
1.58; 95% CI: 1.34–1.85; P<0.0001).
Event rates for MACE and all-cause mortality accord-
ing to the component of high ATR definition are illustrated 
in Figure 3. Following multivariable adjustment, among the 
individual component of high ATR, only DM was associated 
with higher risk of MACE (adjusted HR: 1.57; 95% CI: 1.28–
1.93; P<0.0001). Conversely, PR and PMI had no independent 
effect on MACE risk (adjusted HR: 1.19, 95% CI: 0.89–1.60; 
P=0.22; and adjusted HR: 1.11, 95% CI: 0.77–1.58; P=0.58, 
respectively). Similar findings were observed for all-cause 
mortality, with DM independently associated with this out-
come (adjusted HR: 2.20; 95% CI: 1.65–2.93; P<0.0001), 
whereas PR and PMI were not. The combination of ≥2 risk fac-
tors was associated with the highest risk of MACE (adjusted 
Figure 1. Study population flow diagram. ATR indicates athero-
thrombotic risk; BMS, bare metal stent; DES, drug-eluting stent; 
and RCT, randomized controlled trial.
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HR: 1.78; 95% CI: 1.46–2.16; P<0.0001) and all-cause mor-
tality (adjusted HR: 2.38; 95% CI: 1.80–3.13; P<0.0001).
Early- Versus New-Generation DES in Women at 
High ATR
Three-year outcomes according to ATR status and DES gen-
eration are reported in Table 3 and Figure 4. In women with 
high ATR, the use of new-generation DES was associated with 
significantly lower risk of MACE at 3 years (adjusted HR: 
0.79; 95% CI: 0.63–0.99) compared with early-generation 
DES (Table 3). As well, compared with early-generation DES, 
use of new-generation devices was associated with a signifi-
cant benefit in cardiac mortality (adjusted HR: 0.52; 95% CI: 
0.31–0.88), MI (adjusted HR: 0.68; 95% CI: 0.47–0.98), and 
the composite of all-cause mortality, ST, or MI (adjusted HR: 
0.69; 95% CI: 0.52–0.92). The effects of new-generation DES 
on outcomes were uniform between high-ATR and non–high-
ATR women, without evidence of interaction. Additionally, 
the effect of new-generation DES on the risk of MACE (Fig-
ure I in the Data Supplement) and death, MI, or ST (Figure II 
in the Data Supplement) were uniform across markers of ana-
tomical and procedural complexity, in a magnitude that was 
overall similar with the one observed between high-ATR and 
non-ATR groups.
Kaplan–Meier analyses in the landmark periods for throm-
botic end points according ATR status and DES generation are 
illustrated in Figure 5A (composite of all-cause mortality, MI, 
or ST) and 5B (ST). A significantly lower risk of all-cause 
mortality, MI, or ST and ST was observed within both zero 
and 1 year and between 1 and 3 years with new-generation 
DES in women not at high ATR. Of note, in women not at 
high ATR, rates of ST were low within both the first year 
(0.5%) and between 1 and 3 years (0.1%). In women at high 
ATR, rates of ST in the first year with new-generation DES 
approximated those observed with early-generation devices; 
conversely, after 1 year, new-generation DESs were associ-
ated with improved very-late ST safety compared with early-
generation DES (Figure 5B).
Discussion
To the best of our knowledge, this is the first large report with 
patient-level data from RCTs investigating the safety and effi-
cacy of early- and new-generation DES in women at high risk 
for atherothrombosis undergoing PCI. The main findings of 
our study are the following: (1) the presence of multiple ATR 
factors is associated with increased long-term risk of MACE 
and mortality after DES implantation in women; among these, 
Table 2. Unadjusted and Adjusted 3-Year Clinical Outcomes According to High-Atherothrombotic Risk Status
High-ATR  
(N=5333; 51.0%)
No High-ATR  
(N=5116; 49.0%) P Value* Adjusted HR (95% CI)† P Value‡
All-cause mortality 310 (5.8) 175 (3.4) <0.0001 2.10 (1.66–2.66) <0.0001
Cardiac mortality 183 (4.1) 90 (2.1) <0.0001 2.35 (1.71–3.23) <0.0001
Myocardial infarction 306 (5.7) 203 (4.0) <0.0001 1.32 (1.06–1.64) 0.01
TLR 379 (7.1) 245 (4.8) <0.0001 1.49 (1.22–1.81) <0.0001
Def. or prob. ST 53 (1.0) 33 (0.7) 0.049 2.23 (1.42–3.49) <0.0001
MACE 845 (15.8) 543 (10.6) <0.0001 1.53 (1.34–1.75) <0.0001
All-cause mortality or ST or MI 572 (10.7) 360 (7.0) <0.0001 1.58 (1.34–1.85) <0.0001
ATR indicates atherothrombotic risk; CAD, coronary artery disease; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiac events; MI, 
myocardial infarction; ST, stent thrombosis; and TLR, target-lesion revascularization.
*Log-rank P value.
†Variables included in the model were age, body mass index, hypertension, dyslipidemia, family history of CAD, smoking, presentation with an acute coronary 
syndrome, stent generation, serum creatinine, stent length, and type B2 or C lesions. Hazard ratio expressed with No High-ATR as the reference group.
‡Wald P value.
Figure 2. Cumulative Kaplan–Meier curves for major adverse cardiac events (A) and all-cause mortality (B) at 3 years in women according 
to ATR status. P value from log-rank test. ATR indicates atherothrombotic risk.
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DM was the only one independently associated with higher 
MACE and mortality risk; combination of ≥2 risk factors con-
fers an additive hazard on long-term adverse events; (2) com-
pared with early-generation DES, use of new-generation DES 
is associated with consistent benefit on adverse outcomes in 
women, irrespective of ATR status; in particular, in high-ATR 
women, antithrombotic properties of new-generation devices 
seem to be more evident between one and three years, rather 
within the first year post-PCI; (iii) women not at high-ATR 
treated with new-generation DES had low risk of very-late ST 
at 3 years of follow-up.
Although early-generation DES significantly improved 
the efficacy of PCI compared with bare metal stent, new-
generation platforms substantially enhanced the safety of 
intracoronary stent implantation by mitigating the risk of late 
and very-late platform thrombosis.10 Concerns regarding the 
unrestricted use of DES were mainly because of the higher 
risk of ST observed in high-risk patients or high-risk coronary 
lesions.11 Although studies, such as the Clopidogrel Versus 
Aspirin in Patients at Risk of Ischaemic Events (CAPRIE),12 
a substudy from CHARISMA in high-risk patients,13 and oth-
ers,4,5 demonstrated an improved anti-ischemic efficacy with 
lower risk of adverse cardiac events in high-ATR patients with 
addition of higher potency antiplatelet agents, such evidence 
with new-generation DES, and in particular in women, is 
poor. In the present analysis, we sought to expand the exist-
ing evidence by evaluating the impact of high ATR on clinical 
outcomes in women undergoing PCI with DES and by investi-
gating whether the benefits of new-generation DES are main-
tained in women with and without high-ATR status.
ATR and Outcomes in Women Undergoing PCI
Study-defined high ATR was associated with greater coronary 
artery disease (CAD) severity and complexity and a substantial 
crude and independent increased risk of MACE, mortality, and 
each single ischemic end point in women after DES implan-
tation. Among the available variables in the pooled data set, 
we opted to use 3 well-defined risk factors for future adverse 
events (DM, PR, and PMI) to identify patients at high ATR, 
given the solid supporting literature and their pathobiologi-
cal direct or indirect role in atherothrombosis.3–5,13 Among the 
available baseline clinical variables, we did not opt to include 
clinical presentation within ATR definition because we previ-
ously demonstrated that most of the risk in women associated 
with increased acuteness and severity of CAD across its clinical 
spectrum appears to be confined within 1 year to then decay 
over time.14 Conversely, the included clinical variables might 
have a more durable effect on the risk of adverse events after 
Table 3. Three-Year Clinical Outcomes Between Early- and New-Generation Drug-Eluting Stents According to High-
Atherothrombotic Risk Status
High-ATR Early-Gen 
DES (N=2146)
High-ATR New-Gen 
DES (N=3187)
High-ATR Adjusted 
HR (95% CI)*
No High-ATR Early- 
Gen DES (N=2025)
No High-ATR New- 
Gen DES (N=3091)
No High-ATR Adjusted 
HR (95% CI)*
P for  
Interaction
All-cause mortality 143 (9.6) 167 (5.2) 0.69 (0.47–1.02) 82 (4.1) 93 (3.0) 0.86 (0.47–1.56) 0.88
Cardiac mortality 89 (9.5) 94 (3.6) 0.52 (0.31–0.88) 40 (2.2) 50 (1.9) 0.73 (0.33–1.61) 0.53
Myocardial infarction 133 (6.2) 173 (5.4) 0.68 (0.47–0.98) 100 (4.9) 103 (3.3) 0.82 (0.48–1.39) 0.16
TLR 170 (7.9) 209 (6.6) 1.04 (0.74–1.46) 124 (6.1) 121 (3.9) 0.48 (0.27–0.84) 0.13
Def. or prob. ST 29 (1.4) 24 (0.8) 0.64 (0.25–1.59) 24 (1.8) 9 (0.3) 0.21 (0.03–1.36) 0.09
MACE 375 (17.5) 470 (14.8) 0.79 (0.63–0.99) 261 (12.9) 282 (9.1) 0.68 (0.48–0.96) 0.14
All-cause mortality, 
MI or ST
253 (11.8) 319 (10.0) 0.69 (0.52–0.92) 175 (8.6) 185 (6.0) 0.84 (0.56–1.25) 0.16
ATR indicates atherothrombotic risk; CAD, coronary artery disease; CI, confidence interval; DES, drug-eluting stent; HR, hazard ratio; MACE, major adverse cardiac 
events; MI, myocardial infarction; ST, stent thrombosis; and TLR, target lesion revascularization.
*Variables included in the model were age, body mass index, hypertension, dyslipidemia, family history of CAD, smoking, presentation with an acute coronary 
syndrome, serum creatinine, stent length, and type B2 or C lesions. Hazard ratio expressed with early-generation DES as the reference group.
Figure 3. Cumulative Kaplan–Meier curves for major adverse cardiac events (A) and all-cause mortality (B) at 3 years in women according 
to the atherothrombotic risk factor. P value from log-rank test. ATR indicates atherothrombotic risk; CABG, coronary artery bypass graft; 
MI, myocardial infarction; and PCI, percutaneous coronary intervention.
 at Universitaetsbibliothek Bern on April 20, 2016http://circinterventions.ahajournals.org/Downloaded from 
7  Giustino et al  DES in Women at High Risk for Atherothrombosis 
PCI. We did not include smoking status because the definition 
of current smoking was not available and because the relation-
ship between smoking and adverse outcomes is uncertain.15 
However, although the combination of these risk factors showed 
an additive effect on the risk of adverse events, only DM exhib-
ited an increased and independent risk on MACE and mortality. 
The lack of independent effect of PR and PMI might be related 
to the fact that these 2 clinical variables are a reflection of the 
burden and severity of CAD rather than a direct mediator of the 
overall clinical risk. Although DM is directly involved in the 
pathogenesis of chronic kidney disease, endocrine dysfunction, 
increased thrombogenicity, peripheral arterial disease, and 
cerebrovascular disease,16 the nature of the crude relationship 
between PR and PMI with adverse outcomes is most likely cor-
relative rather than causative.
New-Generation DES in Women at High Risk for 
Atherothrombosis
By optimizing vascular biocompatibility, endothelialization with 
strut coverage, and drug release kinetic, compared with early-
generation DES, new-generation DES significantly improved 
the late and very-late safety of intracoronary DES implantation.10 
Figure 4. Cumulative Kaplan–Meier curves for major adverse cardiac events (A), the composite of all-cause mortality, myocardial infarc-
tion (MI), or stent thrombosis (B), and definite or probable stent thrombosis (C) at 3 years according to atherothrombotic risk status and 
drug-eluting stent generation. P value from log-rank test. ATR indicates atherothrombotic risk; and DES, drug-eluting stent.
Figure 5. Kaplan–Meier curves for the composite of all-cause mortality, myocardial infarction (MI), or definite or probable stent thrombosis 
(A) and definite or probable stent thrombosis (B) in the landmark period of 0 to 1 year and 1 to 3 years in women treated with early- or 
new-generation drug-eluting stents (DES) according to ATR status. P value from log-rank test. ATR indicates atherothrombotic risk.
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However, whether these benefits are maintained in the high-risk 
patient subset, in particular of female sex, is to date unclear. In 
women at high ATR, at 3 years, we observed a significant benefit 
with new-generation DES across all the studied ischemic out-
comes, including cardiac mortality. Moreover, when we looked 
at the relative temporal distribution of event rates through 3 
years, most of the stent-related thrombotic benefit was confined 
to the very-late period (1 to 3 years). In fact, the benefits of new-
generation DES over early-generation DES in high-ATR women 
appear to be related to a substantial improvement in the very-late 
safety, whereas the event rates remain high early after PCI in this 
patient subset. Notably, the rates of ST were exceedingly low 
in women not at high ATR, especially between 1 and 3 years 
(0.1%). These findings have several important clinical implica-
tions: (1) in a contemporary practice with new-generation DES, 
women with CAD at lower risk for atherothrombosis might 
not benefit from prolonged (beyond 6 months or 1 year) dual 
antiplatelet therapy to prevent stent-related thrombotic compli-
cations; instead, these would expose such patients to an unnec-
essary bleeding and possibly mortality risk17,18; (2) conversely, 
women with high ATR, even with new-generation DES, remain 
at high risk for stent-related ischemic complications in the first 
year after PCI, suggesting that completion of at least 1 year of 
a regimen of dual antiplatelet inhibition might be appropriate 
in this patient subset in presence of low risk of bleeding. Con-
sidering that the presence of chronic ATR factors yields a con-
stant risk over time to develop coronary thrombotic events (both 
stent- and non–stent-related),19 the benefits associated with use 
of new-generation DES in this high-risk population are more 
likely to be observed over long-term follow-up rather than early 
after PCI. Therefore in presence of a favorable efficacy (anti-
ischemic) and safety (prohemorrhagic) trade-off, high-ATR 
women might benefit from more potent and prolonged (>1 year) 
platelet inhibition which should be applied with the rationale of 
preventing cerebrovascular, peripheral, and non–DES-related 
coronary atherothrombotic events, rather than those occurring 
within the coronary vascular segment where a new-generation 
DES has been implanted.
Limitations
Notwithstanding our findings rely on individual patient-level, 
high-quality data from prospective, randomized trials with data 
monitoring and event adjudication by clinical event committees, 
several limitations have to be disclosed. First, atherothrombo-
sis is a systemic disease so other clinical variables characterize 
this condition; however, important clinical variables, such as 
documented cerebrovascular disease, documented symptom-
atic peripheral arterial disease, carotid artery disease, diabetic 
nephropathy (baseline serum creatinine was available only in 
half of the study population), and uncontrolled arterial hyperten-
sion or hypercholesterolemia, were not available in the pooled 
data set; therefore, our study-defined population is more likely 
a high-cardiac-ATR rather than a high-systemic-ATR; however, 
the benefits of new-generation DES would be cardiac in nature 
as opposed to an antiplatelet agent that would confer a systemic 
effect and, therefore, acting also on noncoronary arterial vascu-
lature. Second, some trials included in the analysis were per-
formed more than a decade ago, during which clinical practice 
and device technology changed. To reduce the trial effect on 
outcomes, we included trial as a random effect in our adjusted 
analysis. Third, patient population across trials was hetero-
geneous; early trials focused only on stable CAD with simple 
lesion, whereas most recent trials had a tendency to include more 
complex patients and lesions subsets. Fourth, the exclusion of 
male participants from this study precludes sex-specific analy-
sis, limiting the external validity of our findings. Fifth, this has to 
be considered as a post hoc analysis from RCTs not designed to 
specifically assess DES outcomes in women with high ATR. To 
overcome this limitation, we carried out a rigorous multivariable 
adjustment. However, as in any nonrandomized study, our find-
ings are subject to residual confounding on the effect estimates.
Conclusions
Multiple risk factors for atherothrombosis are common in 
women with CAD undergoing PCI with DES and are associ-
ated with a substantial increased risk of MACE and mortal-
ity. Compared with early-generation DES, newer-generation 
DES are associated with a significantly improved safety 
and efficacy in women at high ATR at 3 years after PCI. 
Of note, in women at high ATR, the thrombotic benefit of 
new-generation DES appeared more evident in the very-
late period rather than within 1 year after PCI. The rates of 
ST with new-generation DES in women not at high-ATR 
were low ≤3 years of follow-up. The results of the pres-
ent patient-level pooled analysis underscore the significant 
benefits, and their temporal distribution, of new-generation 
DES in this high-risk subset of patients previously under-
represented in RCTs.
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APPENDIX 
 
Supplementary Tables 
Supplementary Table 1. Characteristics of included randomized controlled trials. CAD: Coronary Artery Disease; BMS: Bare Metal 
Stent; NSTEMI: Non-ST segment Elevation Myocardial Infarction; STEMI: ST segment Elevation Myocardial Infarction; UA: 
Unstable Angina. Cypher and Cordis, Johnson & Johnson, Miami Lakes, FL, USA; Taxus, Boston Scientific, Natick, MA, USA; 
Xience, Abbott Vascular, Santa Clara, CA, USA; Promus, Boston Scientific; Endeavor, Medtronic, Santa Rosa, CA, USA; Resolute, 
Medtronic; Biomatrix, Biosensors, Newport Beach, CA, USA; Nobori, Terumo, Tokyo, Japan; Yukon, Translumina, Hechingen, 
Germany. 
Study Year Patients Women Stents used Key inclusion criteria Key exclusion 
criteria 
RAVEL1 2002 238 58 (24) Cypher, BMS Stable CAD or UA, single de-
novo lesion 
NSTEMI or STEMI 
SIRIUS2 2003 1058 305 (29%) Cypher, BMS  Stable CAD or UA, single de-
novo lesion 
NSTEMI or STEMI 
E-SIRIUS3 2003 352 103 (29%) Cypher, BMS  Stable CAD or UA, single de-
novo lesion 
NSTEMI or STEMI 
C-SIRIUS4 2004 100 31 (31%) Cypher, BMS  Stable CAD or UA, single de-
novo lesion 
NSTEMI or STEMI 
TAXUS I5 2003 61 7 (11%) Taxus, BMS Stable CAD or UA, single lesion NSTEMI or STEMI 
TAXUS II SR6 2003 267 67 (25%) Taxus, BMS  Stable CAD or UA, single de- NSTEMI or STEMI 
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novo lesion 
TAXUS IV7 2004 1314 367 (28%) Taxus, BMS  Stable CAD or UA, single de-
novo lesion 
NSTEMI or STEMI 
TAXUS V8 2005 1156 353 (31%) Taxus, BMS  Stable CAD or UA, single de-
novo lesion 
NSTEMI or STEMI 
SIRTAX9 2005 1012 231 (23%) Cypher, Taxus Stable CAD or UA, single de-
novo lesion 
None 
ENDEAVOR II10 2006 1197 283 (24%) Endeavor, BMS Stable CAD or UA, single de-
novo lesion 
NSTEMI or STEMI 
ENDEAVOR III11 2006 436 133 (31%) Endeavor, Cypher Stable CAD or UA, single de-
novo lesion 
NSTEMI or STEMI 
ENDEAVOR IV12 2010 1548 500 (32%) Endeavor, Taxus Stable CAD or UA, single de-
novo lesion 
NSTEMI or STEMI 
PROTECT13 2012 8709 2061 
(24%) 
Endeavor, Cypher Stable CAD or UA, single de-
novo lesion 
None 
RESOLUTE AC14 2010 2292 529 (23%) Resolute, Xience Stable CAD, UA, NSTEMI or 
STEMI 
None 
TWENTE15 2012 1391 382 (27%) Resolute, Xience Stable CAD, UA or NSTEMI STEMI 
SPIRIT II16 2006 300 80 (27%) Xience, Taxus Stable CAD, UA or 2 de-novo 
lesions 
NSTEMI or STEMI 
SPIRIT III17 2008 1002 314 (31) Xience, Taxus  Stable CAD, UA or 2 de-novo 
lesions 
NSTEMI or STEMI 
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SPIRIT IV18 2010 3687 1189 (32) Xience, Taxus  Stable CAD, UA or 3 de-novo 
lesions 
NSTEMI or STEMI 
COMPARE I19 2010 1800 526 (29%) Xience, Taxus  Stable CAD, UA, NSTEMI or 
STEMI 
None 
BASKET-PROVE20 2010 2314 565 (24%) Xience, Cypher, BMS Stable CAD, UA or acute MI, 
target vessel diameter ≥ 3.0 mm 
None 
EXCELLENT21 2011 1443 512 (35%) Xience, Promus, Cypher Stable CAD, UA, NSTEMI STEMI 
RESET22 2012 3197 742 (23%) Xience, Cypher Stable CAD, UA, NSTEMI or 
STEMI 
None 
PRODIGY23 2012 2013 473 (23%) Xience, Promus, Endeavor, 
Taxus, BMS 
Stable CAD, UA, NSTEMI or 
STEMI 
None 
LEADERS24 2008 1707 430 (25%) Biomatrix, Cypher Stable CAD, UA, NSTEMI or 
STEMI 
None 
COMPARE II25 2013 2707 293 (26%) Nobori, Xience, Promus Stable CAD, UA, NSTEMI or 
STEMI 
None 
ISAR-TEST 426 2009 2603 623 (24%) Yukon, Xience, Cypher Stable CAD, UA, NSTEMI or 
STEMI 
None 
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Supplementary Table 2. Clinical endpoint definitions used across randomized controlled trials. ARC: Academic Research 
Consortium; CK: Creatine-Kinase; ECG = Electrocardiogram; MI: Myocardial Infarction; URL: Upper Reference Limit. 
Trial name Myocardial infarction Target lesion revascularization Stent thrombosis 
RAVEL  Development of Q waves in ≥2 contiguous leads with 
elevated cardiac enzymes or, in the absence of Q 
waves, increase in the CK level ≥2*ULN and 
increased level of CK-MB 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent. 
ARC criteria 
SIRIUS  Development of Q waves in ≥2 contiguous leads with 
elevated cardiac enzymes or, in the absence of Q 
waves, increase in the CK level ≥2*ULN and 
increased level of CK-MB 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent. 
ARC criteria 
E-SIRIUS  Development of Q waves in ≥2 contiguous leads with 
elevated cardiac enzymes or, in the absence of Q 
waves, increase in the CK level ≥2*ULN and 
increased level of CK-MB 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent. 
ARC criteria 
C-SIRIUS  Development of Q waves in ≥2 contiguous leads with 
elevated cardiac enzymes or, in the absence of Q 
waves, increase in the CK level ≥2*ULN and 
increased level of CK-MB 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent. 
ARC criteria 
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TAXUS I  Development of Q waves in ≥2 contiguous leads with 
CK and CK-MB levels elevated above normal 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent. 
ARC criteria 
TAXUS II SR  Development of Q waves in ≥2 contiguous leads or, in 
the absence of Q waves, increase in the CK level 
≥2*ULN and increased level of CK-MB 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent. 
ARC criteria 
TAXUS IV  Development of Q waves in ≥2 contiguous leads or, in 
the absence of Q waves, increase in the CK level 
≥2*ULN and increased level of CK-MB 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent. 
ARC criteria 
TAXUS V  Development of Q waves in ≥2 contiguous leads or, in 
the absence of Q waves, increase in the CK level 
≥2*ULN and increased level of CK-MB 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
SIRTAX  Development of Q waves in ≥2 contiguous leads or, in 
the absence of Q waves, increase in the CK level 
≥2*ULN and increased level of CK-MB or troponin I 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
ENDEAVOR II  Development of Q waves in ≥2 contiguous leads or, in 
the absence of Q waves, increase in the CK level 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
ARC criteria 
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≥2*ULN and increased level of CK-MB stent or within the 5-mm borders proximal or 
distal to the stent 
ENDEAVOR 
III  
Development of Q waves in ≥2 contiguous leads with 
elevated cardiac enzymes or, in the absence of Q 
waves, increase in the CK level ≥2*ULN and 
increased level of CK-MB 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
ENDEAVOR 
IV  
Development of Q waves in ≥2 contiguous leads with 
elevated cardiac enzymes or, in the absence of Q 
waves, increase in the CK level ≥2*ULN and 
increased level of CK-MB 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
   ARC criteria 
PROTECT  II Universal Definition (Thygesen K et al. Circulation 
2007): Periprocedural MI: cardiac biomarkers increase 
≥3*ULN Spontaneous: Typical rise and fall of cardiac 
biomarkers (preferably troponin) with at least 1 value 
>URL and at least 1 of the following: symptoms, ST-
T changes at ECG, pathological Q waves, or imaging 
evidence of ischemia 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
RESOLUTE 
AC  
Extended historical definition (Vranckx et al. 
Eurointervention 2010). In summary: development of 
Q waves in ≥2 contiguous leads and elevated cardiac 
enzymes or, in the absence of Q waves, increase in the 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
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CK level ≥2*ULN and increased level of CK-MB or 
troponin. In patients with acute MI at baseline: if 
cardiac biomarkers still raising new chest pain of 
ischemia equivalent and rise in cardiac biomarkers 
>50% previous level; if cardiac biomarkers have 
returned to normal, CK level ≥2*ULN. 
TWENTE  Extended historical definition (Vranckx et al. 
Eurointervention 2010). In summary: development of 
Q waves in ≥2 contiguous leads and elevated cardiac 
enzymes or, in the absence of Q waves, increase in the 
CK level ≥2*ULN and increased level of CK-MB or 
troponin. In patients with acute MI at baseline: if 
cardiac biomarkers still raising new chest pain of 
ischemia equivalent and rise in cardiac biomarkers 
>50% previous level; if cardiac biomarkers have 
returned to normal, CK level ≥2*ULN. 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
SPIRIT II  Development of Q waves in ≥2 contiguous leads or, in 
the absence of Q waves, a typical rise and fall of CK-
MB (if non-procedural/spontaneous MI, CK-MB >2 
times upper limit of normal; if post PCI, CK-MB >3 
times upper limit of normal; if post CABG, CK-MB 
>5 times upper limit of normal) 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
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SPIRIT III  Development of Q waves in ≥2 contiguous leads with 
elevated cardiac enzymes or, in the absence of Q 
waves, increase in the CK level ≥2*ULN and 
increased level of CK-MB 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
SPIRIT IV  Development of Q waves in ≥2 contiguous leads with 
elevated cardiac enzymes or, in the absence of Q 
waves, increase in the CK level ≥2*ULN and 
increased level of CK-MB 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
COMPARE  Periprocedural MI (in patients without acute MI at 
baseline): any elevation in concentrations of CK 
≥2*ULN and increase in CK-MB or troponin. 
Spontaneous MI: typical rise and fall of troponin or 
CK-MB with at least one of the following: ischemic 
symptoms, development of pathological Q waves, 
ischemic ECG changes, or pathological findings of an 
acute MI 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
BASKET-
PROVE  
Typical rise and fall of cardiac biomarkers (preferably 
troponin) with at least 1 value >URL and at least 1 of 
the following: symptoms, ST-T changes at ECG, 
pathological Q waves, or recent angioplasty. 
Target vessel Revascularization was used ARC criteria 
EXCELLENT  Academic Research Consortium criteria (Cutlip DE et 
al. Circulation 2007) In summary: 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
ARC criteria 
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Periprocedural MI: troponin >3*URL or CK-
MB>3*URL if baseline cardiac biomarkers <URL. 
Stable or decreasing values on 2 samples followed by 
20% increase if baseline cardiac biomarkers >URL. 
Spontaneous MI: troponin >URL or CK-MB >URL 
stent or within the 5-mm borders proximal or 
distal to the stent 
RESET  Periprocedural MI: CK-MB ≥3*ULN or CK ≥3*ULN 
in the absence of CKMB measurement. 
Spontaneous MI: Academic Research Consortium 
criteria (Cutlip DE et al. Circulation 2007), troponin 
>URL or CK-MB >URL 
Revascularisation for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
   ARC criteria 
PRODIGY  II Universal Definition (Thygesen K et al. Circulation 
2007): Periprocedural MI: cardiac biomarkers increase 
≥3*ULN Spontaneous: Typical rise and fall of cardiac 
biomarkers (preferably troponin) with at least 1 value 
>URL and at least 1 of the following: symptoms, ST-
T changes at ECG, pathological Q waves, or imaging 
evidence of ischemia 
Target vessel Revascularisation was used ARC criteria 
LEADERS  Development of Q waves in ≥2 contiguous leads or, in 
the absence of Q waves, increase in the CK level 
≥2*ULN and increased level of CK-MB or troponin I 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
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COMPARE-2  Periprocedural MI (in patients without acute MI at 
baseline):any elevation in concentrations of CK 
≥2*ULN and increase in CK-MB or troponin. 
Spontaneous MI: typical rise and fall of troponin or 
CK-MB with at least one of the following: ischemic 
symptoms, development of pathological Q waves, 
ischemic ECG changes, or pathological findings of an 
acute MI 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
ISAR-TEST 4  Periprocedural MI: CK-MB (or CK) ≥3*ULN and at 
least 50% over the most recent pre-PCI levels, or the 
development of new ECG changes consistent with MI 
and CK-MB (CK) elevation >ULN at 2 measurements 
for patients with stable angina pectoris or NSTE-ACS 
and falling or normal CK-MB (CK) levels. Recurrent 
chest pain lasting .30 min with either new ECG 
changes consistent with second MI or next CK-MB 
(CK) level at least 8–12 h after PCI elevated at least 
50% above the previous level was considered 
procedure-related MI for patients presenting with 
elevated CK-MB (CK) level prior to PCI. 
Spontaneous MI: any CK-MB increase with or 
without the development of Q-waves on ECG. 
Revascularization for ischemia for a stenosis 
of the luminal diameter anywhere within the 
stent or within the 5-mm borders proximal or 
distal to the stent 
ARC criteria 
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Supplementary Figure 1. Risk of death, myocardial infarction or target lesion revascularization 
with early- versus new-generation drug-eluting stents across anatomical and procedural 
subgroups. 
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Supplementary Figure 2. Risk of death, myocardial infarction or stent thrombosis with early- 
versus new-generation drug-eluting stents across anatomical and procedural subgroups. 
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